This company listing is no longer active
V9Z Stock Overview
Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Aceragen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.24 |
| 52 Week High | €11.09 |
| 52 Week Low | €0.24 |
| Beta | 1.2 |
| 1 Month Change | -64.96% |
| 3 Month Change | -84.00% |
| 1 Year Change | -97.16% |
| 3 Year Change | -99.14% |
| 5 Year Change | -99.82% |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| V9Z | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.6% | 0.7% | -0.7% |
| 1Y | -97.2% | -2.1% | 10.1% |
Return vs Industry: V9Z underperformed the German Biotechs industry which returned -5.5% over the past year.
Return vs Market: V9Z underperformed the German Market which returned 10.9% over the past year.
Price Volatility
| V9Z volatility | |
|---|---|
| V9Z Average Weekly Movement | 30.6% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: V9Z's share price has been volatile over the past 3 months.
Volatility Over Time: V9Z's weekly volatility (31%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 26 | John Taylor | www.aceragen.com |
Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich’s Ataxia.
Aceragen, Inc. Fundamentals Summary
| V9Z fundamental statistics | |
|---|---|
| Market cap | €2.02m |
| Earnings (TTM) | -€38.03m |
| Revenue (TTM) | €6.79m |
0.3x
P/S Ratio-0.1x
P/E RatioIs V9Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| V9Z income statement (TTM) | |
|---|---|
| Revenue | US$7.33m |
| Cost of Revenue | US$15.40m |
| Gross Profit | -US$8.06m |
| Other Expenses | US$32.98m |
| Earnings | -US$41.05m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.88 |
| Gross Margin | -110.00% |
| Net Profit Margin | -559.86% |
| Debt/Equity Ratio | 1.3% |
How did V9Z perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/09/05 05:08 |
| End of Day Share Price | 2023/08/30 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aceragen, Inc. is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ulz | Baird |
| Huidong Wang | Barclays |
| Michael King | JMP Securities |